SELLAS Life Sciences Group Files 8-K on Shareholder Vote Matters

TL;DR

SELLAS filed an 8-K detailing shareholder votes - important for governance updates.

AI Summary

On June 20, 2024, SELLAS Life Sciences Group, Inc. filed an 8-K to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and decisions put forth for shareholder approval.

Why It Matters

This filing informs investors about key corporate decisions that have been or will be voted on by shareholders, impacting the company's governance and future direction.

Risk Assessment

Risk Level: low — This is a routine filing reporting on matters submitted to a vote of security holders, not indicating new financial distress or significant operational changes.

Key Players & Entities

• SELLAS Life Sciences Group, Inc. (company) — Registrant
• June 20, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-33958 (company_id) — Commission File Number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq Ca

Filing Documents

• tm2417795d1_8k.htm (8-K) — 35KB
• 0001104659-24-073957.txt ( ) — 205KB
• sls-20240620.xsd (EX-101.SCH) — 3KB
• sls-20240620_lab.xml (EX-101.LAB) — 33KB
• sls-20240620_pre.xml (EX-101.PRE) — 22KB
• tm2417795d1_8k_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Annual Meeting of Stockholders On June 20, 2024, SELLAS Life Sciences Group, Inc. (the "Company") held its Annual Meeting of Stockholders ("Annual Meeting"). There were 30,007,008 shares of common stock, or approximately 51.95% of all outstanding shares, present in person or represented by proxy. At the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below. Proposal 1 The Company's stockholders re-elected each of the following nominees as a Class II director to the Board of the Company to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified. NAME FOR WITHHELD BROKER NON-VOTES David A. Scheinberg 8,633,329 2,721,754 18,651,925 Katherine Bach Kalin 8,808,845 2,546,238 18,651,925 Proposal 2 The Company's stockholders ratified the appointment of Moss Adams LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,778,751 1,743,924 484,333 - Proposal 3 The Company's stockholders approved the non-binding, advisory resolution on the executive compensation of the Company's named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTES 5,992,510 4,808,398 554,175 18,651,925 No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: June 21, 2024 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR